ITeos Therapeutics Inc (NASDAQ:ITOS) has a beta value of 1.26 and has seen 1.28 million shares traded in the last trading session. The company, currently valued at $284.55M, closed the last trade at $7.45 per share which meant it gained $0.83 on the day or 12.54% during that session. The ITOS stock price is -151.68% off its 52-week high price of $18.75 and 35.57% above the 52-week low of $4.80. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.6 million shares traded. The 3-month trading volume is 343.58K shares.
The consensus among analysts is that ITeos Therapeutics Inc (ITOS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.9.
ITeos Therapeutics Inc (NASDAQ:ITOS) trade information
Sporting 12.54% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ITOS stock price touched $7.45 or saw a rise of 0.67%. Year-to-date, ITeos Therapeutics Inc shares have moved -2.99%, while the 5-day performance has seen it change 34.72%. Over the past 30 days, the shares of ITeos Therapeutics Inc (NASDAQ:ITOS) have changed 8.28%. Short interest in the company has seen 1.83 million shares shorted with days to cover at 4.77.
Wall Street analysts have a consensus price target for the stock at $17, which means that the shares’ value could jump 56.18% from current levels. The projected low price target is $17.0 while the price target rests at a high of $17.0. In that case, then, we find that the current price level is -128.19% off the targeted high while a plunge would see the stock gain -128.19% from current levels.
ITeos Therapeutics Inc (ITOS) estimates and forecasts
The company’s shares have lost -22.48% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -78.63%.
5 analysts offering their estimates for the company have set an average revenue estimate of 1.8M for the current quarter. 5 have an estimated revenue figure of 1.8M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -34.39% over the past 5 years. Earnings growth for 2025 is a modest -21.27% while over the next 5 years, the company’s earnings are expected to decrease by -5.39%.
ITOS Dividends
ITeos Therapeutics Inc is expected to release its next earnings report on 2025-Mar-04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders
Insiders own 1.13% of the company shares, while shares held by institutions stand at 91.06% with a share float percentage of 92.10%. Investors are also buoyed by the number of investors in a company, with ITeos Therapeutics Inc having a total of 193.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 3.73 million shares worth more than $55.37 million. As of 2024-06-30, BLACKROCK INC. held 9.3983% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 3.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $52.2 million and represent 8.8598% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.24% shares in the company for having 855.64 shares of worth $6.37 million while later fund manager owns 719.67 shares of worth $5.36 million as of Mar 31, 2025 , which makes it owner of about 1.88% of company’s outstanding stock.
